Abstract: The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
Type:
Grant
Filed:
March 14, 2006
Date of Patent:
February 27, 2007
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Michael G. Yang, Simon Haydar, Wenting Chen, Christopher D. McClung, Emilie J. Calvello, David M. Zawrotny
Abstract: The present invention describes a method of concurrent imaging in a mammal comprising: a) administering to said mammal a vitronectin receptor targeted imaging agent and a perfusion imaging agent; and b) concurrently detecting the vitronectin target imaging agent bound at the vitronectin receptor and the perfusion imaging agent; and c) forming an image from the detection of said vitronectin receptor targeted imaging agent and said perfusion imaging agent.
Abstract: This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Application
Filed:
September 18, 2006
Publication date:
February 1, 2007
Applicant:
BRISTOL-MYERS SQUIBB PHARMA COMPANY
Inventors:
Richard Olson, Hong Liu, Lorin Thompson
Abstract: Corticotropin releasing factor (CRF) antagonists of Formula (I): and its use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
Abstract: The present invention provides 4-(bis(2-methoxyethyl)amino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-[1,5-a]-pyrazolo-1,3,5-triazine benzenesulfonate salt and a crystalline polymorph thereof. Further provided are pharmaceutical compositions containing the salt and methods of treating CRF-related disorders using said salt.
Type:
Grant
Filed:
November 10, 2004
Date of Patent:
December 26, 2006
Assignee:
Bristol-Myers Squibb Pharma Co.
Inventors:
Paul J. Gilligan, Shelly Renee Rabel Riley, Paul A. Meenan
Abstract: This invention relates to a novel method of screening for inhibitors of beta-amyloid production, and thereby identifying such inhibitors as therapeutics for neurological and other disorders involving APP processing and beta-amyloid production. This invention also relates to identifying macromolecules involved in APP processing and beta-amyloid production. Furthermore, inhibitors identified by the screening method of the present invention are useful in the treatment of neurological disorders, such as Alzheimer's disease, which involve elevated levels of A? peptides.
Type:
Grant
Filed:
December 11, 2003
Date of Patent:
December 26, 2006
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Robert Zaczek, Richard E. Olson, Dietmar A. Seiffert, Lorin Andrew Thompson
Abstract: This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Application
Filed:
July 26, 2006
Publication date:
November 23, 2006
Applicant:
BRISTOL-MYERS SQUIBB PHARMA COMPANY
Inventors:
Richard Olson, Thomas Maduskuie, Lorin Thompson
Abstract: Methods and apparatus for separating ions of metallic elements are provided. Preferred methods utilize a hydrophobic chelating extractant, such as an organophosphorus compound, adsorbed onto carbon or graphite fibers in the form of felt. Also described is a new thallium-201 generator that comprises a column containing an acidic organophosphorus extractant adsorbed on carbon or graphite fibers, and a yttrium-90 generator system comprised of two extraction columns designed to selectively absorb yttrium-90 at different pH, to enable the separation of yttrium-90 from strontium-90. The two columns are connected in series for stepwise separation. The yttrium-90 product is freed from residual strontium-90 and metal contaminants and can be eluted from the second column with dilute acid, acetate buffer, water or saline for labeling biological targeted molecules. The new generator system provides rapid and efficient separation of yttrium-90 and is amenable to both scale-up and automation.
Type:
Grant
Filed:
January 22, 2004
Date of Patent:
November 21, 2006
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Robert E. Lewis, Fu-Min Su, Timothy A. Lane, Keith R. Olewine, Peter S. Holton
Abstract: This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Application
Filed:
July 25, 2006
Publication date:
November 16, 2006
Applicant:
BRISTOL-MYERS SQUIBB PHARMA COMPANY
Inventors:
Richard Olson, Thomas Maduskuie, Lorin Thompson
Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of inflammatory diseases such as asthma and other allergic diseases.
Type:
Grant
Filed:
January 21, 2005
Date of Patent:
October 24, 2006
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Dean A Wacker, John V Duncia, Joseph B Santella, III., Daniel S Gardner
Abstract: This invention relates to novel arylalkyl cyclic amine derivatives. This invention also relates to chemokine receptor antagonists that are be effective as therapeutic agents and/or preventive agents for diseases such as atherosclerosis, rheumatoid arthritis, transplant rejection, psoriasis, asthma, ulcerative colitis, glomerulonephritis, multiple sclerosis, pulmonary fibrosis, and myocarditis, in which tissue infiltration of blood monocytes and lymphocytes plays a major role in the initiation, progression or maintenance of the disease. Furthermore, chemokine receptor antagonists also inhibit the interaction of viruses, which attack blood monocytes and lymphocytes, through the use of a chemokine receptor. One such example is the HIV virus.
Type:
Grant
Filed:
May 12, 2000
Date of Patent:
October 24, 2006
Assignee:
Bristol-Myers Squibb Pharma Research Labs, Inc.
Abstract: This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Grant
Filed:
December 28, 2004
Date of Patent:
September 26, 2006
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Richard E. Olson, Hong Liu, Lorin A. Thompson
Abstract: This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Application
Filed:
February 6, 2006
Publication date:
September 21, 2006
Applicant:
BRISTOL-MYERS SQUIBB PHARMA COMPANY
Inventors:
Qi Han, Hong Liu, Richard Olson, Michael Yang
Abstract: This invention relates to novel lactams having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Type:
Grant
Filed:
July 6, 2005
Date of Patent:
September 5, 2006
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Richard E. Olson, Thomas P. Maduskuie, Lorin Andrew Thompson
Abstract: The present invention describes novel compounds of the formula: (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
Type:
Grant
Filed:
January 21, 2003
Date of Patent:
August 15, 2006
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Edward H. Cheesman, John A. Barrett, Alan P. Carpenter, Jr., Milind Rajopadhye, Michael Sworin
Abstract: The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
Type:
Grant
Filed:
February 26, 2004
Date of Patent:
July 4, 2006
Assignee:
Bristol-Myers Squibb Pharma Co.
Inventors:
Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Michael G. Yang, Simon Haydar, Wenting Chen, Christopher D. McClung, Emilie J. Calvello, David M. Zawrotny
Abstract: This invention relates to novel cyclic malonamides having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A?-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to ?-amyloid production such as Alzheimer's disease and Down's Syndrome.
Abstract: Thus the present invention describes diagnostic agents comprising a diagnostic metal and a compound, wherein the compound comprises: 1-10 targeting moieties; a chelator; and 0-1 linking groups between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to the diagnostic metal. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in diagnosis of diseases associated with MMPs.
Type:
Grant
Filed:
August 21, 2003
Date of Patent:
June 13, 2006
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Alan P. Carpenter, Jr., Milind Rajopadhye
Abstract: Antibodies directed against an antigenic determinant of high molecular weight kininogen domain 5, particularly a determinant located in the region formed by light chain amino acids Gly(440) to Lys(502), inhibit angiogenesis.
Type:
Application
Filed:
January 30, 2006
Publication date:
June 1, 2006
Applicants:
Temple University - Of The Commonwealth Of Higher Education, Bristol-Myers Squibb Pharma Company
Abstract: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
Type:
Grant
Filed:
July 18, 2003
Date of Patent:
May 30, 2006
Assignee:
Bristol-Myers Squibb Pharma Company
Inventors:
Milind Rajopadhye, D. Scott Edwards, John A. Barrett, Alan P. Carpenter, Jr., Thomas D Harris, Stuart D Heminway, Shuang Liu, Singh R Prahlad